5,225 results match your criteria Alopecia Areata


Is there a lınk between alopecıa areata and gut?

J Cosmet Dermatol 2022 May 17. Epub 2022 May 17.

University of Health Science Dışkapı Yıldırım Beyazıt Training and Research Hospital, Department of Biochemistry, 06110, Ankara, Turkey.

Background: There may be an association between increased intestinal permeability and the progression of alopecia areata (AA).

Objective: The present study aimed to investigate the role of intestinal permeability in the etiopathogenesis of AA and its association with the severity of the disease.

Methods: Serum zonulin levels of 70 patients with AA who were not receiving any systemic treatment and of 70 healthy control subjects were measured. Read More

View Article and Full-Text PDF

Blaschko-linear alopecia areata in a child, an exceedingly rare variant.

Int J Dermatol 2022 May 16. Epub 2022 May 16.

Department of Dermatology, Qatif Central Hospital, Qatif Health Network, First Health Cluster, Qatif, Saudi Arabia.

View Article and Full-Text PDF

Loss of 'Epidermal Melanin Unit' Integrity in Human Skin During Melanoma-Genesis.

Front Oncol 2022 27;12:878336. Epub 2022 Apr 27.

The Charles Institute of Dermatology, School of Medicine, University College Dublin, Dublin, Ireland.

Cutaneous melanoma can be a most challenging neoplasm of high lethality, in part due to its extreme heterogeneity and characteristic aggressive and invasive nature. Indeed, its moniker 'the great masquerader' reflects that not all melanomas are created equal in terms of their originating cellular contexts, but also that melanoma cells in the malignant tumor can adopt a wide range of different cell states and variable organotropism. In this review, we focus on the early phases of melanomagenesis by discussing how the originating pigment cell of the melanocyte lineage can be influenced to embark on a wide range of tumor fates with distinctive microanatomical pathways. Read More

View Article and Full-Text PDF

Letter in Reply: Alopecia areata after SARS-CoV-2 vaccination.

JAAD Case Rep 2022 May 7. Epub 2022 May 7.

UCF Health, Department of Dermatology.

View Article and Full-Text PDF

A case of alopecia universalis after a mild COVID-19 infection.

JAAD Case Rep 2022 May 7. Epub 2022 May 7.

University of California, Irvine, Department of Dermatology, Irvine, CA, USA.

View Article and Full-Text PDF

Identity and psychological distress in alopecia areata.

Authors:
Nigel Hunt

Br J Dermatol 2022 May 13. Epub 2022 May 13.

Department of Medicine, University of Nottingham, Nottingham, UK.

View Article and Full-Text PDF

Tofacitinib Therapy for Alopecia Areata is not Associated with Adverse Events during COVID-19 Infection.

J Am Acad Dermatol 2022 May 9. Epub 2022 May 9.

Department of Dermatology, Columbia University Irving Medical Center, New York, NY 10032. Electronic address:

View Article and Full-Text PDF

Treatment of Resistant Alopecia areata with Tofacitinib.

Authors:
Ganesh Avhad

Int J Trichology 2022 Mar-Apr;14(2):60-61. Epub 2022 Apr 4.

Skin and Hair World, Mumbai, Maharashtra, India.

The activity of tofacitinib for Alopecia areata (AA) has been reported but mainly from the western countries. We report the case of a young female Indian patient with AA unresponsive to therapy. Improvements in terms of hair regrowth were observed within 2 months of treatment with oral tofacitinib 5 mg BID tablets. Read More

View Article and Full-Text PDF

Alopecia Areata Universalis in the Onset of Autoimmune Polyendocrine Syndrome Type III C.

Int J Trichology 2022 Mar-Apr;14(2):62-64. Epub 2022 Apr 4.

Pediatrics I Clinic, Mureş Emergency Hospital, Tîrgu Mureş, Romania.

Alopecia areata (AA) is an organ-specific autoimmune disease which affects hair follicles. It usually presents as a transient patchy hair loss, but it can sometimes progress into more severe forms such as AA totalis or AA universalis (AAU). Different autoimmune diseases, as well as autoimmune polyglandular syndromes (APS), have been associated with AA, especially with Type I and Type II APS. Read More

View Article and Full-Text PDF

Reply to "Vitamin D status in scarring and nonscarring alopecia".

J Am Acad Dermatol 2022 May 5. Epub 2022 May 5.

Department of Dermatology, New York Medical College School of Medicine, Valhalla, NY, United States. Electronic address:

View Article and Full-Text PDF

Frontiers in Lichen Planopilaris and Frontal Fibrosing Alopecia Research: Pathobiology Progress and Translational Horizons.

JID Innov 2022 May 1;2(3):100113. Epub 2022 Mar 1.

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida, USA.

Lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) are primary, lymphocytic cicatricial hair loss disorders. These model epithelial stem cell (SC) diseases are thought to result from a CD8 T-cell‒dominated immune attack on the hair follicle (HF) SC niche (bulge) after the latter has lost its immune privilege (IP) for as yet unknown reasons. This induces both apoptosis and pathological epithelial‒mesenchymal transition in epithelial SCs, thus depletes the bulge, causes fibrosis, and ultimately abrogates the HFs' capacity to regenerate. Read More

View Article and Full-Text PDF

Photobiomodulation Therapy With Different Wavebands for Hair Loss: A Systematic Review and Meta-Analysis.

Dermatol Surg 2022 Apr 25. Epub 2022 Apr 25.

Research Center for Tissue Repair and Regeneration Affiliated to the Medical Innovation Research Division and 4th Medical Center of Chinese PLA General Hospital, Beijing, P. R. China.

Background: Photobiomodulation is a promising therapy for hair loss with negligible side effects. However, the reported effects of photobiomodulation therapy for hair loss are inconsistent.

Objective: To assess the curative effect of photobiomodulation therapy for the treatment of hair loss. Read More

View Article and Full-Text PDF

Association between psoriasis and alopecia areata: A systematic review and meta-analysis.

J Dermatol 2022 May 5. Epub 2022 May 5.

Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

The association between psoriasis and alopecia areata has not been thoroughly investigated. The objective of this study is to investigate the association of psoriasis with alopecia areata. An electronic search was conducted in August 2021. Read More

View Article and Full-Text PDF

Treatment satisfaction and response in patients with severe alopecia areata under treatment with diphenylcyclopropenone.

Health Sci Rep 2022 May 26;5(3):e602. Epub 2022 Apr 26.

Department of Dermatology, Razi Hospital Tehran University of Medical Sciences Tehran Iran.

Background And Aims: Alopecia areata (AA) is an autoimmune disease of hair follicles. Treatments currently include topical and intralesional corticosteroids and contact immunotherapy; however, the overall prognosis is usually unfavorable. In severe AA, topical immunotherapy with diphenylcyclopropenone (DPCP) is preferred. Read More

View Article and Full-Text PDF

Fractional CO laser versus microneedling as a transepidermal drug delivery system for the treatment of alopecia areata: A clinical dermoscopic evaluation.

Dermatol Ther 2022 May 4:e15553. Epub 2022 May 4.

Dermatology and Venereology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt.

New treatment modalities are rising for better clinical improvement in alopecia areata. This work aims to evaluate the efficacy of fractional CO laser and microneedling as a transepidermal drug delivery in cases with alopecia areata. The study included 30 patients with alopecia areata. Read More

View Article and Full-Text PDF

Baricitinib in Alopecia Areata.

N Engl J Med 2022 05;386(18):1751-1752

From the Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield (A.M.), the Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford (M.H.), and the Centre for Dermatology Research, University of Manchester, Manchester Academic Health Science Centre and National Institute for Health Research Manchester Biomedical Research Centre, Manchester (M.H.) - all in the United Kingdom.

View Article and Full-Text PDF

Content validity of five single-item instruments in adolescents with alopecia areata.

Authors:
Toni M Klein

Br J Dermatol 2022 05;186(5):763-764

Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg, 20246, Germany.

View Article and Full-Text PDF

Exploring the effects of Chinese herbal ingredients on the signaling pathway of alopecia and the screening of effective Chinese herbal compounds.

J Ethnopharmacol 2022 Apr 26;294:115320. Epub 2022 Apr 26.

Institute of Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150040, China. Electronic address:

Ethnopharmacological Relevance: alopecia is a hair disorder that can add a significant medical and psychological burden to patients. Currently, the FDA-approved drugs for the treatment of androgenetic alopecia (AGA) are minoxidil and finasteride and immunosuppressives are therapeutic options for alopecia areata (AA), but the objective adverse effects and high cost of these treatments reduce patient compliance and thus the effectiveness of the drugs. Traditional Chinese medicine (TCM) has good efficacy, a high safety profile and low treatment costs, but its mechanism of action is still not fully understood. Read More

View Article and Full-Text PDF

[Janus kinase inhibitors for the treatment of alopecia areata].

Hautarzt 2022 May 28;73(5):336-343. Epub 2022 Apr 28.

Abteilung für Dermatologie, Hadassah-Klinik und Medizinische Fakultät, Hebräische Universität Jerusalem, PO Box 12000, 9112001, Jerusalem, Israel.

Alopecia areata is a common condition that leads to nonscarring hair loss. It can be severe and lead to complete hair loss of the scalp or the whole body. In more severe cases, the disease can be very recalcitrant to treatment and result in a significant impairment of the quality of life of the patients. Read More

View Article and Full-Text PDF

RNAi-based modulation of IFN-γ signaling in skin.

Mol Ther 2022 Apr 27. Epub 2022 Apr 27.

RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA. Electronic address:

Aberrant activation of interferon (IFN)-γ signaling plays a key role in several autoimmune skin diseases, including lupus erythematosus, alopecia areata, vitiligo, and lichen planus. Here, we identify fully chemically modified small interfering RNAs (siRNAs) that silence the ligand binding chain of the IFN-γ receptor (IFNGR1), for the modulation of IFN-γ signaling. Conjugating these siRNAs to docosanoic acid (DCA) enables productive delivery to all major skin cell types local to the injection site, with a single dose of injection supporting effective IFNGR1 protein reduction for at least 1 month in mice. Read More

View Article and Full-Text PDF

Risks of Comorbidities in Patients With Palmoplantar Pustulosis vs Patients With Psoriasis Vulgaris or Pompholyx in Korea.

JAMA Dermatol 2022 Apr 27. Epub 2022 Apr 27.

Department of Dermatology, Seoul National University College of Medicine, Seoul, South Korea.

Importance: Palmoplantar pustulosis (PPP) has been reported to be accompanied by systemic conditions. However, the risks of comorbidities in patients with PPP have rarely been evaluated.

Objective: To assess the risks of comorbidities in patients with PPP compared with patients with psoriasis vulgaris or pompholyx. Read More

View Article and Full-Text PDF

Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study.

J Allergy Clin Immunol 2022 Apr 22. Epub 2022 Apr 22.

Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's & St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom. Electronic address:

Background: Atopic dermatitis (AD) is associated with immune dysregulation, but epidemiologic data on the pattern of autoimmune comorbidity in people with AD are limited.

Objective: We sought to determine the risk of autoimmune conditions in people newly diagnosed with AD.

Methods: Retrospective cohort analysis (January 2009 to December 2018), using the UK-based Oxford-Royal College of General Practitioners Research and Surveillance Centre primary care database. Read More

View Article and Full-Text PDF

Psychocutaneous Medicine in Iraq: Current Status and Recommendations.

Prim Care Companion CNS Disord 2022 Apr 21;24(2). Epub 2022 Apr 21.

University of California Los Angeles, Los Angeles, California.

To evaluate the knowledge and attitudes of Iraqi dermatologists regarding understanding, diagnosing, and treating psychocutaneous disorders.

An online survey questionnaire was randomly distributed among Iraqi dermatologists through Google Forms in August 2020. The dermatologists were asked to provide information on their understanding of psychodermatology, referral patterns, level of comfort in managing psychocutaneous disorders, awareness of community resources, and interest in learning more about psychodermatology. Read More

View Article and Full-Text PDF

Topical immunotherapy treatment of alopecia areata with diphenylcyclopropenone: Regulatory T cells as biomarkers for treatment response.

Dermatol Ther 2022 Apr 18:e15522. Epub 2022 Apr 18.

1st Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Treatment of alopecia areata is often challenging, especially for patients with extended disease. Contact immunotherapy with diphenylcyclopropenone (DPCP) has been reported as an effective topical treatment but the exact immunologic mechanism of diverting the immune response is still unknown. We investigated the efficacy of topical immunotherapy with DPCD in acute, intermediate, and chronic lesions of AA and the response rate was associated with perifollicular infiltrate of T regulatory cells. Read More

View Article and Full-Text PDF

Prediction of the Mechanism of Shaoyao Gancao Decoction in the Treatment of Alopecia Areata by Network Pharmacology and Its Preliminary Verification Study.

Evid Based Complement Alternat Med 2022 7;2022:5764107. Epub 2022 Apr 7.

Department of Dermatology, China-Japan Friendship Hospital, Beijing 100029, China.

Objective: To explore the mechanism of Shaoyao Gancao decoction (SGD) in treatment of alopecia areata (AA) by network pharmacology and animal experiments.

Methods: Based on the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP), the components and targets of SGD were determined. Then, the related targets of AA were retrieved from DrugBank, GeneCards, OMIM, and DisGeNET databases. Read More

View Article and Full-Text PDF

TNFα inhibitor biosimilars associated with alopecia areata. Case-based review.

Rheumatol Int 2022 Jun 16;42(6):1113-1117. Epub 2022 Apr 16.

Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece.

Alopecia areata (AA) is a common non-scaring hair loss associated with many inflammatory and autoimmune disorders. Anti-tumor necrosis factor alpha (TNFα) therapy is used to treat many chronic inflammatory disorders and has been proven to be effective and relatively safe. However, several immune-mediated skin reactions have been described with the use of TNFα inhibitors, among them AA. Read More

View Article and Full-Text PDF

Imiquimod-enhanced immunotherapy with diphencyprone for patients with alopecia areata.

Dermatol Ther 2022 Apr 14:e15516. Epub 2022 Apr 14.

Dermatology Department, Trichology Unit, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria, University of Alcalá, Madrid, Spain.

Topical immunotherapy with dyphencyprone (DPCP) is widely used in patients with alopecia areata (AA). It can produce a contact dermatitis that is believed to decrease Th1 response, predominant in AA. It has been shown that imiquimod (IMQ), a topical immunomodulator drug, can produce sensitization to DPCP in patients that do not show signs of contact dermatitis when exposed to DPCP. Read More

View Article and Full-Text PDF

Anagen Effluvium after Neurointerventional Radiation: Trichoscopy as a Diagnostic Ally.

Skin Appendage Disord 2022 Mar 14;8(2):102-107. Epub 2021 Sep 14.

Universidad Autónoma de Nuevo León, Facultad de Medicina, Servicio de Dermatología Hospital Universitario "Dr. José Eleuterio González,", Monterrey, Mexico.

Minimally invasive procedures for vascular brain lesions are being performed more frequently. Radiation exposure caused by endovascular embolization of cerebral aneurysms may give rise to nonscarring scalp alopecia located in the treated area. Clinical and trichoscopic features of this type of alopecia are similar to alopecia areata (AA). Read More

View Article and Full-Text PDF

Economic Impact of Home-Use versus Office-Use Diphenylcyclopropenone in Extensive Alopecia Areata.

Skin Appendage Disord 2022 Mar 22;8(2):108-117. Epub 2021 Nov 22.

Skin Laser and Surgery Department, Dontum Hospital, Nakhon Pathom, Thailand.

Introduction: Diphenylcyclopropenone (DPCP) is the medication of choice for the treatment of severe alopecia areata (AA) according to AA treatment guidelines. Precise initiation and application are important factors for successful treatment. However, it is difficult for patients who live far away to visit their doctor weekly. Read More

View Article and Full-Text PDF